|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
| We’re going down soon, to move to a new Data Center today. We’ll be up ASAP. Sorry. |
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 3/07/24 Harvard Bioscience Inc. 10-K 12/31/23 113:9.7M Globenewswire Inc./FA |
Document/Exhibit Description Pages Size
1: 10-K Annual Report HTML 1.71M
2: EX-21.1 Subsidiaries List HTML 31K
3: EX-23.1 Consent of Expert or Counsel HTML 30K
8: EX-97 Clawback Policy re: Recovery of Erroneously HTML 38K
Awarded Compensation
4: EX-31.1 Certification -- §302 - SOA'02 HTML 35K
5: EX-31.2 Certification -- §302 - SOA'02 HTML 35K
6: EX-32.1 Certification -- §906 - SOA'02 HTML 31K
7: EX-32.2 Certification -- §906 - SOA'02 HTML 31K
14: R1 Document And Entity Information HTML 100K
15: R2 Consolidated Balance Sheets HTML 137K
16: R3 Consolidated Balance Sheets (Parentheticals) HTML 43K
17: R4 Consolidated Statements of Operations HTML 102K
18: R5 Consolidated Statements of Comprehensive Loss HTML 60K
19: R6 Consolidated Statements of Comprehensive Loss HTML 33K
(Parentheticals)
20: R7 Consolidated Statements of Stockholders' Equity HTML 89K
21: R8 Consolidated Statements of Cash Flows HTML 120K
22: R9 Insider Trading Arrangements HTML 49K
23: R10 Note 1 - Organization HTML 34K
24: R11 Note 2 - Summary of Significant Accounting HTML 113K
Policies
25: R12 Note 3 - Accumulated Other Comprehensive Loss HTML 52K
26: R13 Note 4 - Goodwill and Intangible Assets HTML 78K
27: R14 Note 5 - Balance Sheet Information HTML 73K
28: R15 Note 6 - Restructuring and Other Exit Costs HTML 58K
29: R16 Note 7 - Employee Benefit Plans HTML 111K
30: R17 Note 8 - Leases HTML 68K
31: R18 Note 9 - Long-term Debt HTML 56K
32: R19 Note 10 - Derivatives HTML 43K
33: R20 Note 11 - Fair Value Measurements HTML 43K
34: R21 Note 12 - Stock-Based Compensation HTML 100K
35: R22 Note 13 - Revenues HTML 92K
36: R23 Note 14 - Income Tax HTML 130K
37: R24 Note 15 - Commitments and Contingent Liabilities HTML 37K
38: R25 Note 16 - Litigation Settlement HTML 35K
39: R26 Note 17 - Product Line Disposition HTML 34K
40: R27 Note 18 - Government Assistance HTML 36K
41: R28 Significant Accounting Policies (Policies) HTML 172K
42: R29 Note 2 - Summary of Significant Accounting HTML 50K
Policies (Tables)
43: R30 Note 3 - Accumulated Other Comprehensive Loss HTML 51K
(Tables)
44: R31 Note 4 - Goodwill and Intangible Assets (Tables) HTML 82K
45: R32 Note 5 - Balance Sheet Information (Tables) HTML 77K
46: R33 Note 6 - Restructuring and Other Exit Costs HTML 55K
(Tables)
47: R34 Note 7 - Employee Benefit Plans (Tables) HTML 114K
48: R35 Note 8 - Leases (Tables) HTML 72K
49: R36 Note 9 - Long-term Debt (Tables) HTML 49K
50: R37 Note 10 - Derivatives (Tables) HTML 44K
51: R38 Note 11 - Fair Value Measurements (Tables) HTML 40K
52: R39 Note 12 - Stock-Based Compensation (Tables) HTML 99K
53: R40 Note 13 - Revenues (Tables) HTML 94K
54: R41 Note 14 - Income Tax (Tables) HTML 129K
55: R42 Note 2 - Summary of Significant Accounting HTML 77K
Policies (Details Textual)
56: R43 Note 2 - Summary of Significant Accounting HTML 39K
Policies - Property, Plant and Equipment (Details)
57: R44 Note 2 - Summary of Significant Accounting HTML 64K
Policies - Schedule of Basic and Diluted Earnings
Per Share (Details)
58: R45 Note 3 - Accumulated Other Comprehensive Loss - HTML 49K
Changes in Each Component of Other Comprehensive
Loss, Net of Tax (Details)
59: R46 Note 4 - Goodwill and Intangible Assets (Details HTML 35K
Textual)
60: R47 Note 4 - Goodwill and Intangible Assets - Change HTML 35K
in Carrying Amount of Goodwill (Details)
61: R48 Note 4 - Goodwill and Intangible Assets - HTML 52K
Intangible Assets (Details)
62: R49 Note 4 - Goodwill and Intangible Assets - Future HTML 45K
Amortization Expense of Intangible Assets
(Details)
63: R50 Note 5 - Balance Sheet Information (Details HTML 33K
Textual)
64: R51 Note 5 - Balance Sheet Information - Inventories HTML 38K
(Details)
65: R52 Note 5 - Balance Sheet Information - Property, HTML 46K
Plant and Equipment (Details)
66: R53 Note 5 - Balance Sheet Information - Other Current HTML 42K
Liabilities (Details)
67: R54 Note 5 - Balance Sheet Information - Long-lived HTML 35K
Assets by Geographic Area (Details)
68: R55 Note 6 - Restructuring and Other Exit Costs - HTML 48K
Restructuring and Other Exit Charges (Details)
69: R56 Note 7 - Employee Benefit Plans (Details Textual) HTML 46K
70: R57 Note 7 - Employee Benefit Plans - Defined Benefit HTML 41K
Pension Expense (Details)
71: R58 Note 7 - Employee Benefit Plans - Change in Fair HTML 44K
Value of Plan Assets (Details)
72: R59 Note 7 - Employee Benefit Plans - Change in HTML 52K
Benefit Obligations (Details)
73: R60 Note 7 - Employee Benefit Plans - Recognized in HTML 33K
Consolidated Balance Sheets (Details)
74: R61 Note 7 - Employee Benefit Plans - Weighted Average HTML 33K
Assumptions (Details)
75: R62 Note 7 - Employee Benefit Plans - Fair Value and HTML 45K
Asset Allocations of Pension Benefits (Details)
76: R63 Note 7 - Employee Benefit Plans - Fair Value of HTML 38K
Plan Assets By Fair Value Hierarchy (Details)
77: R64 Note 8 - Leases - Lease Expense (Details) HTML 37K
78: R65 Note 8 - Leases - Supplemental Balance Sheet HTML 41K
Information Related to Operating Leases (Details)
79: R66 Note 8 - Leases - Supplemental Cash Flow HTML 33K
Information Related to Operating Leases (Details)
80: R67 Note 8 - Leases - Future Minimum Lease Payments HTML 48K
(Details)
81: R68 Note 9 - Long-term Debt (Details Textual) HTML 71K
82: R69 Note 9 - Long-term Debt - Breakdown of Borrowings HTML 47K
(Details)
83: R70 Note 9 - Long Term Debt - Debt Maturity (Details) HTML 37K
84: R71 Note 10 - Derivatives (Details Textual) HTML 36K
85: R72 Note 10 - Derivatives - Derivative Instruments HTML 34K
(Details)
86: R73 Note 10 - Derivatives - The Effect of Derivatives HTML 34K
Designated as Cash Flow Hedging Instruments
(Details)
87: R74 Note 11 - Fair Value Measurements - Assets and HTML 50K
Liabilities Measured on a Recurring Basis
(Details)
88: R75 Note 12 - Stock-Based Compensation (Details HTML 57K
Textual)
89: R76 Note 12 - Stock-Based Compensation - Stock-based HTML 39K
Compensation Expense (Details)
90: R77 Note 12 - Stock-Based Compensation - Black Scholes HTML 42K
Assumptions (Details)
91: R78 Note 12 - Stock-Based Compensation - Activity of HTML 71K
Restricted Stock and Restricted Stock Units
(Details)
92: R79 Note 12 - Stock-Based Compensation - Stock-Based HTML 50K
Payment Awards (Details)
93: R80 Note 13 - Revenues (Details Textual) HTML 31K
94: R81 Note 13 - Revenues - Disaggregation of Revenue HTML 41K
(Details)
95: R82 Note 13 - Revenues - Revenue by Geographic HTML 40K
Destination (Details)
96: R83 Note 13 - Revenues - Deferred Revenue (Details) HTML 38K
97: R84 Note 13 - Revenues - Allowance for Doubtful HTML 36K
Accounts (Details)
98: R85 Note 13 - Revenues - Warranties (Details) HTML 35K
99: R86 Note 14 - Income Tax (Details Textual) HTML 61K
100: R87 Note 14 - Income Tax - Income Tax Expense HTML 48K
(Details)
101: R88 Note 14 - Income Tax - Income Tax Rate HTML 59K
Reconciliation (Details)
102: R89 Note 14 - Income Tax - Pre-tax Income From HTML 38K
Continuing Operations (Details)
103: R90 Note 14 - Income Tax - Deferred Tax Assets and HTML 74K
Liabilities (Details)
104: R91 Note 14 - Income Tax - Unrecognized Tax Benefits HTML 40K
(Details)
105: R92 Note 15 - Commitments and Contingent Liabilities HTML 33K
(Details Textual)
106: R93 Note 16 - Litigation Settlement (Details Textual) HTML 53K
107: R94 Note 17 - Product Line Disposition (Details HTML 40K
Textual)
108: R95 Note 18 - Government Assistance (Details Textual) HTML 35K
110: XML IDEA XML File -- Filing Summary XML 211K
113: XML XBRL Instance -- hboi20231231_10k_htm XML 2.15M
109: EXCEL IDEA Workbook of Financial Report Info XLSX 163K
10: EX-101.CAL XBRL Calculations -- hbio-20231231_cal XML 212K
11: EX-101.DEF XBRL Definitions -- hbio-20231231_def XML 1.55M
12: EX-101.LAB XBRL Labels -- hbio-20231231_lab XML 1.34M
13: EX-101.PRE XBRL Presentations -- hbio-20231231_pre XML 1.64M
9: EX-101.SCH XBRL Schema -- hbio-20231231 XSD 249K
111: JSON XBRL Instance as JSON Data -- MetaLinks 591± 953K
112: ZIP XBRL Zipped Folder -- 0001171843-24-001239-xbrl Zip 336K
| HTML Editor |
EXHIBIT 32.1
CERTIFICATION OF PERIODIC FINANCIAL REPORT
PURSUANT TO 18 U.S.C. SECTION 1350
The undersigned officer of Harvard Bioscience, Inc. (the “Company”) hereby certifies to her knowledge that the Company’s annual report on Form 10-K for the year ended December 31, 2023 to which this certification is being furnished as an exhibit (the “Report”), as filed with the Securities and Exchange Commission on the date hereof, fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and that the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. This certification is provided solely pursuant to 18 U.S.C. Section 1350 and Item 601(b)(32) of Regulation S-K (“Item 601(b)(32)”) promulgated under the Securities Act of 1933, as amended (the “Securities Act”), and the Exchange Act. In accordance with clause (ii) of Item 601(b)(32), this certification (A) shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liability of that section, and (B) shall not be deemed to be incorporated by reference into any filing under the Securities Act or the Exchange Act, except to the extent that the Company specifically incorporates it by reference.
|
Date: March 7, 2024 |
/s/ JENNIFER COTE |
|
Name: Jennifer Cote |
|
|
Title: Chief Financial Officer |
| This ‘10-K’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 3/7/24 | 4, 8-K | ||
| For Period end: | 12/31/23 | |||
| List all Filings | ||||